Clinical Characteristics and Hearing Outcomes of Otitis Media With ANCA-Associated Vasculitis: A Four-Group Comparison Including Unclassified Disease

Objective: To characterize clinical features, hearing outcomes, and relapse patterns across disease categories of otitis media with antineutrophil cytoplasmic antibody–associated vasculitis (OMAAV), with particular focus on unclassified OMAAV. Study design: Retrospective cohort study. Setting: Tertiary referral university hospital. Patients: Fifty-six patients (89 ears) diagnosed with OMAAV between 2009 and 2025, classified as eosinophilic granulomatosis with polyangiitis (n=16), granulomatosis with polyangiitis (GPA, n=17), microscopic polyangiitis (n=8), or unclassified OMAAV (n=15). Interventions: Immunosuppressive therapy, including systemic corticosteroids with or without additional immunosuppressants. Main outcome measures: Time from disease onset to treatment initiation, pure-tone audiometric outcomes, and cumulative incidence of otologic and systemic relapse. Results: Patients with unclassified OMAAV demonstrated a significantly longer time to treatment initiation and more severe hearing impairment at presentation compared with those with other subtypes. Across the entire cohort, longer time to treatment initiation was moderately correlated with greater baseline hearing loss. Despite presenting with the most severe hearing impairment, patients with unclassified OMAAV showed hearing improvement comparable to that in the other groups following immunosuppressive therapy. The 3-year cumulative incidence of otologic relapse did not differ significantly among groups. In contrast, systemic relapse occurred most frequently in GPA. Among patients with GPA, temporal analysis revealed heterogeneous patterns of otologic and systemic relapse, and otologic relapse did not consistently precede systemic exacerbation. Conclusions: Unclassified OMAAV is prone to diagnostic delay due to an isolated otologic presentation, resulting in severe hearing loss at onset; however, preserved responsiveness to treatment highlights the importance of early diagnosis and prompt immunosuppressive therapy. Otologic relapse does not consistently precede systemic relapse in granulomatosis with polyangiitis, underscoring the need for careful systemic evaluation regardless of otologic disease activity.

Authors

Publication Details

Journal
Otology & Neurotology
Published
2026-10-08
DOI
https://doi.org/10.1097/mao.0000000000005086
Primary Topic
Vasculitis and related conditions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical Characteristics and Hearing Outcomes of Otitis Media With ANCA-Associated Vasculitis: A Four-Group Comparison Including Unclassified Disease

Akihiro Homma, Keishi Fujiwara, Kimiko Hoshino, Yuji Nakamaru et al.
Otology & Neurotology
Vasculitis and related conditions
article

Clinical Characteristics and Hearing Outcomes of Otitis Media With ANCA-Associated Vasculitis: A Four-Group Comparison Including Unclassified Disease

Akihiro Homma, Keishi Fujiwara, Kimiko Hoshino, Yuji Nakamaru, Kento Komatsuda, Hideaki Takeda, Shinya Morita
article en

Abstract

Objective: To characterize clinical features, hearing outcomes, and relapse patterns across disease categories of otitis media with antineutrophil cytoplasmic antibody–associated vasculitis (OMAAV), with particular focus on unclassified OMAAV. Study design: Retrospective cohort study. Setting: Tertiary referral university hospital. Patients: Fifty-six patients (89 ears) diagnosed with OMAAV between 2009 and 2025, classified as eosinophilic granulomatosis with polyangiitis (n=16), granulomatosis with polyangiitis (GPA, n=17), microscopic polyangiitis (n=8), or unclassified OMAAV (n=15). Interventions: Immunosuppressive therapy, including systemic corticosteroids with or without additional immunosuppressants. Main outcome measures: Time from disease onset to treatment initiation, pure-tone audiometric outcomes, and cumulative incidence of otologic and systemic relapse. Results: Patients with unclassified OMAAV demonstrated a significantly longer time to treatment initiation and more severe hearing impairment at presentation compared with those with other subtypes. Across the entire cohort, longer time to treatment initiation was moderately correlated with greater baseline hearing loss. Despite presenting with the most severe hearing impairment, patients with unclassified OMAAV showed hearing improvement comparable to that in the other groups following immunosuppressive therapy. The 3-year cumulative incidence of otologic relapse did not differ significantly among groups. In contrast, systemic relapse occurred most frequently in GPA. Among patients with GPA, temporal analysis revealed heterogeneous patterns of otologic and systemic relapse, and otologic relapse did not consistently precede systemic exacerbation. Conclusions: Unclassified OMAAV is prone to diagnostic delay due to an isolated otologic presentation, resulting in severe hearing loss at onset; however, preserved responsiveness to treatment highlights the importance of early diagnosis and prompt immunosuppressive therapy. Otologic relapse does not consistently precede systemic relapse in granulomatosis with polyangiitis, underscoring the need for careful systemic evaluation regardless of otologic disease activity.

Otology & Neurotology
Openalex Percentile: Top 12%
Vasculitis and related conditions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.